Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat

Clovis Oncology, Inc. today announced the presentation of data from the TRITON3 Phase 3 trial in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. The presentation... | October 27, 2022

Related Keywords

Colorado ,United States ,Boulder ,American ,Alanh Bryce ,Patrickj Mahaffy , ,Clovis Oncology Inc ,National Cancer Institute ,Nasdaq ,Exchange Commission ,Prostate Cancer Foundation ,American Cancer Society ,Clinical Cancer Research ,Division Of Hematology ,Clovis Oncology ,Homologous Recombination Deficiency ,Medical Oncology ,Mayo Clinic ,Clinical Trial ,Annual Prostate Cancer Foundation ,Fact Sheets ,Acute Myeloid Leukemia ,Prescribing Information ,Private Securities Litigation Reform Act ,Annual Report ,Advanced Prostate Cancer ,Current Therapies ,Future Promise ,Cold Spring Harb Perspect Med ,Prostate Cancer Clinical States ,Estimates Using ,Dynamic Progression Model ,New Horizon ,Prostate Cancer ,Nc Stock Exchange ,News ,Information ,Press Release ,Lovis ,Oday ,Nnounced ,The ,Presentation ,F ,Data ,Rom ,Triton3 ,Hase ,Trial ,N ,Pen ,Ith ,Metastatic ,Prostate ,Dancer ,Arca ,Dr ,Tm ,He Clvs Us1894641000 ,